PARIS--29 Aug--PRNewswire-AsiaNet/ InfoQuest
- This release is not intended for US and Canadian media
AstraZeneca today announced the results of a sub-analysis from the VOYAGER individual patient data meta-analysis, which demonstrated that the possibility of reaching the 100 mg/dL LDL-C goal with statin treatment is dependent upon baseline LDL-C and the choice and dose of statin. CRESTOR(TM) (rosuvastatin) helped more patients reach an LDL-C goal of